{"entity":{"id":"zev-wainberg","kind":"person","name":"Zev A. Wainberg","aka":[],"tldr":"Led NAPOLI 3, the trial that made NALIRIFOX a first-line option for metastatic pancreatic cancer.","summary":"Zev Wainberg was principal investigator of NAPOLI 3, which showed NALIRIFOX (liposomal irinotecan, oxaliplatin, fluorouracil) improves survival over gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer, and has led FGFR2b (bemarituzumab) and claudin 18.2 trials in gastric cancer. He co-directs GI oncology at UCLA and runs early-phase GI trials.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainberg%20ZA%5BAuthor%5D%20pancreatic%20NAPOLI"}],"tags":["pancreatic","gastric","trialist"],"related":[],"cancers":["pancreatic","gastric"],"sections":[],"technologies":[],"targets":["cldn18-2","fgfr2"],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":["napoli-3","fortitude-101"],"people":[],"bottlenecks":[],"keyPapers":["paper-napoli-3-lancet-2023"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Co-Director, GI Oncology Program, UCLA Jonsson Comprehensive Cancer Center","institutionId":"ucla-jonsson","specialisms":["Pancreatic cancer","Gastro-oesophageal cancer","Early drug development","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wainberg%20ZA%5BAuthor%5D%20pancreatic%20NAPOLI"}],"papers":[{"title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)01366-1"},{"title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT)","journal":"Lancet Oncology","year":2022,"doi":"10.1016/S1470-2045(22)00603-9"},{"title":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAPOLI-3+NALIRIFOX+Wainberg+Lancet"}]},"route":"/people/zev-wainberg/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"trial":[{"id":"fortitude-101","kind":"trial","name":"FORTITUDE-101","route":"/trials/fortitude-101/"},{"id":"napoli-3","kind":"trial","name":"NAPOLI 3","route":"/trials/napoli-3/"}],"paper":[{"id":"paper-daraxonrasib-pancreatic-n-engl-j-med-2026","kind":"paper","name":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer","route":"/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/"},{"id":"paper-napoli-3-lancet-2023","kind":"paper","name":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","route":"/key-papers/paper-napoli-3-lancet-2023/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}]}}